Skip to main content
Premium Trial:

Request an Annual Quote

Bionano Genomics Commences Public Stock Offering

NEW YORK – Bionano Genomics said after the close of the market on Wednesday that it has commenced a public offering of 13.8 million shares of its common stock and warrants to purchase another 13.8 million shares of common stock.

According to a preliminary prospectus filed with the US Securities and Exchange Commission, each share is being sold together with a warrant to purchase one share. Shares and warrants can only be purchased together but will be issued separately and will be separable immediately. Warrants will be exercisable immediately and will expire five years from the date of issuance.

The firm did not list an offering price per share or exercise price for the warrants, but estimated that the net proceeds would be "approximately $13.6 million based on an assumed offering price of $1.09 per share and accompanying warrant," which was the last reported sales price of its common stock on Sept. 17.

Bionano Genomics markets the Saphyr optical genome mapping system for large-scale structural variant analysis. The San Diego-based firm went public in August 2018.

Last month, the firm reported second quarter revenues of $2.2 million, a 36 percent decrease year-over-year that it attributed to a reduction in both instrument and consumables sales. Its net loss for the quarter was $7.7 million more than double the loss in the prior-year period. As of June 30, the firm had $15.3 million in cash and cash equivalents.

In morning trading on the Nasdaq, shares of Bionano were down 9 percent at $.96.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.